Retrospective analysis of patients’ experience to intravesical Bacillus Calmette-Guerin (BCG)

Original Citation


This version is available at http://eprints.hud.ac.uk/id/eprint/23464/

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:

- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

http://eprints.hud.ac.uk/
Why & what did we do?

Why?

• Gold standard
• Bladder cancer incidence rates are highest in developed countries, especially Northern America and Europe
• BCG treatment induction & maintenance has significant benefits, but also has significant side effects that tend to be seen within the first 12 months of treatment
• To analyse the reasons for treatment interruption in everyday clinical practice in a large district hospital
How did we do it?

- Appropriate ethical approval
- Quantitative data
  - 01/01/04 – 31/12/11
  - Retrospective case note review of 234 cases
  - Diagnosis of NMIBC, grade 3 Ta/1 or CIS, aged 18 years or over
  - Conaught Strain
  - Administered as per SWOG
  - Collected using a specially designed data extraction tool
  - Convenience sample
  - Analysed through IBM SPSS v20
What did we find?

• Issues
  – Data extraction tool
  – Paper to electronic
  – Recorded information

• Results
  – 61% > 70yrs. From these:
    – 92% completed induction, 80% started maintenance
    – 56% completed 1 year and 5% completed 3 years
    – 43% received counselling
    – 10% nurse specialist contact details
    – 65% had at least 1 symptom (45% within 35 days)
    – 40% experienced pain
Conclusion & next steps

• Conclusion
  – Severe toxicity resulted in discontinuation of therapy in the majority
  – The majority withdraw in the first year
  – Surprising that those who had contact with a nurse specialist or received written information were more likely to withdraw
  – Targeted support

• Next steps
  – Interview patients who have withdrawn for their experience
  – Look at the consultation e.g. grade of Dr
  – Review our practice